Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial

Open access
Jones, Heather A., Antonini, Ninja, Hart, Augustinus A.M., Peterse, Johannes L., Horiot, Jean-Claude, Collin, Françoise, Poortmans, Philip M., Oei, S. Bing, Collette, Laurence, Struikmans, Henk, Van den Bogaert, Walter F., Fourquet, Alain, Jager, Jos J., Schinagl, Dominic A.X., Wárlám-Rodenhuis, Carla C., Bartelink, Harry·2009·Journal of Clinical Oncology

Abstract

Purpose: To investigate the long-term impact of pathologic characteristics and an extra boost dose of 16 Gy on local relapse, for stage I and II invasive breast cancer patients treated with breast conserving therapy (BCT). Patients and Methods: In the European Organisation for Research and Treatment of Cancer boost versus no boost trial, after whole breast irradiation, patients with microscopically complete excision of invasive tumor, were randomly assigned to receive or not an extra boost dose of 16 Gy. For a subset of 1,616 patients central pathology review was performed. Results: The 10-year cumulative risk of local breast cancer relapse as a first event was not significantly influenced if the margin was scored negative, close or positive for invasive tumor or ductal carcinoma in situ according to central pathology review (log-rank P = .45 and P = .57, respectively). In multivariate analysis, high-grade invasive ductal carcinoma was associated with an increased risk of local relapse (P = .026; hazard ratio [HR], 1.67), as was age younger than 50 years (P < .0001; HR, 2.38). The boost dose of 16 Gy significantly reduced the local relapse rate (P = .0006; HR, 0.47). For patients younger than 50 years old and in patients with high grade invasive ductal carcinoma, the boost dose reduced the local relapse from 19.4% to 11.4% (P = .0046; HR, 0.51) and from 18.9% to 8.6% (P = .01; HR, 0.42), respectively. Conclusion: Young age and high-grade invasive ductal cancer were the most important risk factors for local relapse, while margin status had no significant influence. A boost dose of 16 Gy significantly reduced the negative effects of both young age and high-grade invasive cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.21.5764

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 239

Metadata

Authors
Jones, H. A., Antonini, N., Hart, A. A. M., Peterse, J. L., Horiot, J.-C., Collin, F., Poortmans, P. M., Oei, S. B., Collette, L., Struikmans, H., Van den Bogaert, W. F., Fourquet, A., Jager, J. J., Schinagl, D. A. X., Wárlám-Rodenhuis, C. C., & Bartelink, H.
Venue
Journal of Clinical Oncology
Published
2009-10-20
Volume
27
Issue
30
Pages
4939-4947
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2123553402
Cited by
239
References
5
FWCI
6.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial. https://app.cochat.ai/papers/10.1200/jco.2008.21.5764
The paper
Jones, H. A., Antonini, N., Hart, A. A. M., Peterse, J. L., Horiot, J.-C., Collin, F., Poortmans, P. M., Oei, S. B., Collette, L., Struikmans, H., Van den Bogaert, W. F., Fourquet, A., Jager, J. J., Schinagl, D. A. X., Wárlám-Rodenhuis, C. C., & Bartelink, H. (2009). Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.5764

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.